Pharma BD Deal Intelligence
AstraZeneca's $2B licensing deal for Jacobio's pan-KRAS inhibitor targets a mutation class that has proven brutally hard to drug, giving AstraZeneca a shot at global rights to a differentiated KRAS-mutant cancer asset. The option-based structure limits AstraZeneca's upfront exposure while it validates the molecule in a still-unresolved competitive field.
AstraZeneca has found another potential gold nugget in China, this time offering as much as $2 billion to Jacobio Pharma to work on an early-stage pan-KRAS…
AstraZeneca strengthens China ties with planned $15B investment. The article references AstraZeneca's broader China strategy that includes the Jacobio Pharma…
AstraZeneca reaches $2 billion license agreement with Jacobio for pan-KRAS inhibitor JAB-23E73.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AstraZeneca licensed a pan-KRAS inhibitor from Jacobio Pharma for global development and commercialization.
Jacobio's pan-KRAS inhibitor (JAB-23E73/glecirasib class successor) is positioned in a crowded and rapidly maturing KRAS-targeted oncology landscape. Competition groups by MOA class: mutant-selective KRAS G12C inhibitors, pan-KRAS/KRAS multi-mutant inhibitors, KRAS G12D selective inhibitors, and upstream/downstream pathway agents. In the KRAS G12C class, Amgen's Lumakras (sotorasib, FDA-approved 2021 for NSCLC and KRAS G12C mCRC with panitumumab in 2024) and Mirati/BMS' Krazati (adagrasib, approved 2022 NSCLC and 2024 mCRC with cetuximab) are the anchor products; mCRC-specific G12C response rates remain below 50% ORR, leaving headroom. Revolution Medicines leads the pan-KRAS/multi-selective class with RMC-6236 (daraxonrasib, pan-RAS(ON), Phase 3 RASolute-302 in mPDAC and colorectal trials ongoing) and RMC-9805 (KRAS G12D, Phase 1). BI's BI 1701963 (SOS1 inhibitor, upstream) and Amgen's AMG 510 next-gen agents are also progressing. In KRAS G12D specifically, Astellas' ASP3082 and Jacobio's own glecirasib (KRAS G12C-selective, NMPA approved China 2024) share pipeline shelf space. Upstream/downstream competitors include SHP2 inhibitors (RMC-4630, TNO155) and MEK inhibitors (trametinib). Commercial takeaway: pan-KRAS is the most competitively valuable node; AstraZeneca is buying optionality against Revolution Medicines' pan-RAS leadership.
AstraZeneca licensed pan-KRAS inhibitor from Jacobio for global development and commercialization.
Recently closed deal. Pan-KRAS is high-value target. Clinical development planning underway.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. (this deal) | 2025 | $2.0B | 70 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2025 deals · AstraZeneca PLC deals · Oncology deals